Gene · 259197
Papers4,252
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 4,252
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Immunoregulatory functions and therapeutic potential of natural killer cell-derived extracellular vesicles in chronic diseases. | Front Immunol | 2023 | 38239346 | PubTator, text mining | PubMed |
| Current status and future perspective of natural killer cell therapy for cancer. | Med Rev (2021) | 2023 | 38235405 | PubTator, text mining | PubMed |
| The Combination of Bioavailable Concentrations of Curcumin and Resveratrol Shapes Immune Responses While Retaining the Ability to Reduce Cancer Cell Survival. | Int J Mol Sci | 2023 | 38203402 | PubTator, text mining | PubMed |
| NK3.3-Derived Extracellular Vesicles Penetrate and Selectively Kill Treatment-Resistant Tumor Cells. | Cancers (Basel) | 2023 | 38201518 | PubTator, text mining | PubMed |
| Optimizing the cryopreservation and post-thaw recovery of natural killer cells is critical for the success of off-the-shelf platforms. | Front Immunol | 2023 | 38193082 | PubTator, text mining | PubMed |
| Ovarian cancer treatment and natural killer cell-based immunotherapy. | Front Immunol | 2023 | 38187402 | PubTator, text mining | PubMed |
| Implications of oral dysbiosis and HPV infection in head and neck cancer: from molecular and cellular mechanisms to early diagnosis and therapy. | Front Oncol | 2023 | 38179168 | PubTator, text mining | PubMed |
| Protocol of the HISTOTHERM study: assessing the response to hyperthermia and hypofractionated radiotherapy in recurrent breast cancer. | Front Oncol | 2023 | 38169879 | PubTator, text mining | PubMed |
| Combining bioinformatics and machine learning algorithms to identify and analyze shared biomarkers and pathways in COVID-19 convalescence and diabetes mellitus. | Front Endocrinol (Lausanne) | 2023 | 38169604 | PubTator, text mining | PubMed |
| Targeting the immune microenvironment for ovarian cancer therapy. | Front Immunol | 2023 | 38164130 | PubTator, text mining | PubMed |
| Synergistic treatment strategy: combining CAR-NK cell therapy and radiotherapy to combat solid tumors. | Front Immunol | 2023 | 38162672 | PubTator, text mining | PubMed |
| Unravelling the cellular response to the SARS-COV-2 vaccine in inflammatory bowel disease patients on biologic drugs. | Sci Rep | 2023 | 38155275 | PubTator, text mining | PubMed |
| Single-cell RNA-seq analyses inform necroptosis-associated myeloid lineages influence the immune landscape of pancreas cancer. | Front Immunol | 2023 | 38149248 | PubTator, text mining | PubMed |
| Alternative immune checkpoints in immunoregulatory profile of cancer stem cells. | Heliyon | 2023 | 38144305 | PubTator, text mining | PubMed |
| Hepatitis D infection induces IFN-β-mediated NK cell activation and TRAIL-dependent cytotoxicity. | Front Immunol | 2023 | 38143742 | PubTator, text mining | PubMed |
| The Role of NKG2D and Its Ligands in Autoimmune Diseases: New Targets for Immunotherapy. | Int J Mol Sci | 2023 | 38139373 | PubTator, text mining | PubMed |
| Insights into the Tumor Microenvironment-Components, Functions and Therapeutics. | Int J Mol Sci | 2023 | 38139365 | PubTator, text mining | PubMed |
| Nicotinamide-Expanded Allogeneic Natural Killer Cells with CD38 Deletion, Expressing an Enhanced CD38 Chimeric Antigen Receptor, Target Multiple Myeloma Cells. | Int J Mol Sci | 2023 | 38139060 | PubTator, text mining | PubMed |
| CD200/CD200R: Bidirectional Role in Cancer Progression and Immunotherapy. | Biomedicines | 2023 | 38137547 | PubTator, text mining | PubMed |
Biomarkers in Adult-Type Diffuse Gliomas: Elevated Levels of Circulating Vesicular Heat Shock Protein 70 Serve as a Biomarker in Grade 4 Glioblastoma and Increase NK Cell Frequencies in Grade 3 Glioma. | Biomedicines | 2023 | 38137456 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/259197/papers?page=12